Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies  - Report - MDSpire

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

Eugene M. & Christine E. Lynn Cancer Institute has treated its first patient with tarlatamab, marking an important milestone in the expansion of advanced cancer therapies available to patients in Palm Beach County and the surrounding region.

  • May 7, 2026

  • 3 min

Share

Clinical Report: Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab

Overview

The Eugene M. & Christine E. Lynn Cancer Institute has successfully treated its first patient with tarlatamab.

Background

The introduction of tarlatamab represents a significant advancement in treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC).

Data Highlights

No numerical data available in the source material.

Key Findings

  • Tarlatamab is a DLL3-directed CD3 T-cell engager approved for adults with ES-SCLC.
  • The FDA granted accelerated approval for tarlatamab on May 16, 2024, based on response rates in the DeLLphi-301 trial.
  • Traditional approval was granted on November 19, 2025, based on overall survival benefits demonstrated in the phase 3 DeLLphi-304 trial.
  • The median overall survival with tarlatamab was 13.6 months compared to 8.3 months with investigator’s-choice chemotherapy.
  • Common adverse reactions include cytokine release syndrome, fatigue, and pyrexia.
  • Coordinated care among healthcare professionals is critical for the successful delivery of tarlatamab.

Clinical Implications

The availability of tarlatamab at the Lynn Cancer Institute allows for access to advanced cancer therapies.

Conclusion

The treatment of the first patient with tarlatamab at Lynn Cancer Institute marks a significant milestone.

Related Resources & Content

  1. FDA, FDA, 2024 -- FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer
  2. The ASCO Post, ASCO Post, 2025 -- Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC
  3. The ASCO Post, ASCO Post, 2025 -- Tarlatamab and Anti–PD-1 Therapy as First-Line Maintenance for ES-SCLC
  4. The ASCO Post, ASCO Post, 2026 -- SCLC: Small Study Tests Efficacy of CTCs in Predicting Response to Tarlatamab
  5. baptist health south florida — First Patient Treated with Proton Therapy at Lynn Cancer Institute
  6. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer | FDA
  7. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer | FDA
  8. https://cancerneo.ru/wp-content/uploads/2024/11/nccn_small_cell_lung_cancer_2025_v2.pdf

Original Source(s)

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

  • May 7, 2026

Related Content

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min
ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

  • 1 min
2026 ASCO Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.

  • July 2, 2026

  • 1 min